Integrin-mediated Activation of Focal Adhesion Kinase Is Independent of Focal Adhesion Formation or Integrin Activation
STUDIES WITH ACTIVATED AND INHIBITORY β3CYTOPLASMIC DOMAIN MUTANTS*
- From the Departments of ‡Medicine,§Pharmacology, and ¶Cell Biology and Anatomy,‖The Center for Thrombosis and Hemostasis, University of North Carolina, Chapel Hill, North Carolina 27599
Abstract
Integrin αIIbβ3functions as the fibrinogen receptor on platelets and mediates platelet aggregation and clot retraction. Among the events that occur during either “inside-out” or “outside-in” signaling through αIIbβ3 is the phosphorylation of focal adhesion kinase (pp125FAK) and the association of pp125FAK with cytoskeletal components. To examine the role of pp125FAK in these integrin-mediated events, pp125FAK phosphorylation and association with the cytoskeleton was determined in cells expressing two mutant forms of αIIbβ3: αIIbβ3(D723A/E726A), a constitutively active integrin in which the putative binding site for pp125FAK is altered, and αIIbβ3(F727A/K729E/F730A), in which the putative binding site for α-actinin is altered. Both mutants were expressed on the cell surface and were able to bind ligand, either spontaneously or upon activation. Whereas cells expressing αIIbβ3(D723A/E726A) were able to form focal adhesions and stress fibers upon adherence to fibrinogen, cells expressing αIIbβ3(F727A/K729E/F730A) adhere to fibrinogen, but had reduced focal adhesions and stress fibers. pp125FAK is recruited to focal adhesions in adherent cells expressing αIIbβ3(D723A/E726A) and is phosphorylated in adherent cells or in cells in suspension in the presence of fibrinogen. In adherent cells expressing αIIbβ3(F727A/K729E/F730A), pp125FAK was phosphorylated despite reduced formation of focal adhesions and stress fibers. We conclude that activation of pp125FAK can be dissociated from two important events in integrin signaling, the assembly of focal adhesions in adherent cells and integrin activation following ligand occupation.
Footnotes
-
↵* This work was supported by National Institutes of Health Grant HL45100.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵** To whom correspondence should be addressed: Division of Hematology-Oncology, University of North Carolina, 932 Faculty Laboratory Office Bldg., 231H/CB# 7035, Chapel Hill, NC 27599. Tel.: 919-966-3311; Fax: 919-966-7639.
-
↵1 The abbreviations used are: FITC, fluorescein isothiocyanate; PCR, polymerase chain reaction; DMEM, Dulbecco’s modified Eagle’s medium; PBS, phosphate-buffered saline; BSA, bovine serum albumin; DTT, dithiothreitol; CHO, Chinese hamster ovary.
-
↵2 S. Lyman, S. Gidwitz, and G. C. White II, unpublished observations.
-
- Received April 4, 1997.
- Revision received June 6, 1997.











